Search results for " young"

showing 10 items of 404 documents

Cross-lagged associations between study and work engagement dimensions during young adulthood

2014

The present four-wave longitudinal study investigated the cross-lagged associations between three study and work engagement dimensions (e.g. energy, absorption, and dedication) over the transition from post-comprehensive studies to higher education or work. Various antecedents (e.g. gender, GPA) and consequences (e.g. satisfaction in life, education and work, well-being, and educational outcomes) of the three engagement dimensions were also examined. The study is part of the longitudinal Finnish Educational Transitions (FinEdu) study, and followed 851 participants from age 17 to 23. The developmental dynamics showed that, in particular, students’ study- and work-related energy predicted fee…

Longitudinal studyHigher educationstudy and work engagementbusiness.industry4. EducationWork engagementEnergy (esotericism)media_common.quotation_subjectLife satisfactionAbsorption (psychology)dedicationFinnish young adultsDevelopmental psychologyWork (electrical)Feelinglife-satisfactionstudy and work transitionPsychologybusinessabsorptionSocial psychologyta515General Psychologyenergymedia_commonThe Journal of Positive Psychology
researchProduct

Barn og unge i familieterapi : en litteraturstudie om hvordan barn og unge opplever å være deltager i familieterapi

2014

Masteroppgave i psykisk helsearbeid ME504 Universitetet i Agder 2014 The aim of this paper is to bring forth knowledge about children and young people's statements about how it is to be a participant in family therapy. To work out and produce this knowledge a literature review has been used as method. An extensive search was conducted in different databases. It turned out to be little research in this field of research. The articles this study is based on are all English, and concerns children and young people's statements about their experience of being participants in family therapy. There are a total of 7 articles included in this study, with participants from 5 to 22 years. The findings…

ME504VDP::Medical disciplines: 700::Health sciences: 800Children and young people ; family therapy ; social constructivism ; language ; play ; facilitated methodical approach
researchProduct

The EORTC computer-adaptive tests measuring physical functioning and fatigue exhibited high levels of measurement precision and efficiency

2013

Objectives: The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group is developing a computer-adaptive test (CAT) version of the EORTC Quality of Life Questionnaire (QLQ-C30). We evaluated the measurement properties of the CAT versions of physical functioning (PF) and fatigue (FA) and compared these with the corresponding QLQ-C30 scales. Study Design and Setting: Based on international samples of more than 1,000 cancer patients, we simulated CAT administration of varying numbers of items and compared the resulting scores with those based on all items in the respective item pools. Furthermore, the relative validity (RV) of CATs was compared with that of th…

MESH: FatigueMaleEpidemiologyMESH: Aged 80 and over0302 clinical medicinePhysical functioningQuality of lifeNeoplasmsSurveys and QuestionnairesActivities of Daily LivingStatisticsMESH: NeoplasmsDiagnosis Computer-Assisted030212 general & internal medicineFatigueReliability (statistics)MathematicsMESH: AgedAged 80 and overMESH: Middle AgedMiddle Agedhumanities3. Good healthMESH: Reproducibility of ResultsLevel of measurementMESH: Young AdultData Interpretation Statistical030220 oncology & carcinogenesis/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingFemaleAdultmedicine.medical_specialtyAdolescentMean squared errorSensitivity and SpecificityYoung Adult03 medical and health sciencesSDG 3 - Good Health and Well-beingotorhinolaryngologic diseasesmedicineHumansMESH: Surveys and QuestionnairesAgedMESH: AdolescentMESH: HumansMESH: Activities of Daily LivingMESH: Diagnosis Computer-AssistedMESH: Quality of LifeReproducibility of ResultsMESH: Adultsocial sciencesMESH: MaleMESH: Sensitivity and SpecificitySample size determinationQuality of LifePhysical therapy[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieComputerized adaptive testingMESH: Data Interpretation StatisticalMESH: FemaleRelative validity
researchProduct

Alcoholic Beverage and Meal Choices for the Prevention of Noncommunicable Diseases: A Randomized Nutrigenomic Trial

2018

Background. Noncommunicable diseases (NCDs) are the first cause of death worldwide. Mediterranean diet may play a crucial role in the prevention of NCDs, and the presence of wine in this diet could play a positive role on health. Methods. 54 healthy volunteers consumed one of the following beverages: red (RW) or white wine (WW), vodka (VDK), and/or Mediterranean meal (MeDM) and high-fat meal (HFM). Results. OxLDL-C changed significantly between baseline versus HFM, MeDM versus HFM, and HFM versus HFM + RW (p<0.05). Significant upregulation of catalase (CAT) was observed only after RW. Conversely, WW, VDK, RW + MeDM, HF + WW, and HF + VDK determined a significant downregulation of CAT gen…

Male0301 basic medicineAgingGPX1AntioxidantMediterranean dietmedicine.medical_treatmentWineMediterranean030204 cardiovascular system & hematologyDiet Mediterraneanmedicine.disease_causeBiochemistryAntioxidantsNutrigenomicsGlutathione Peroxidase GPX10302 clinical medicineSettore MED/49 - Scienze Tecniche Dietetiche Applicatechemistry.chemical_classificationMeallcsh:CytologyAlcoholic BeveragesGlutathione peroxidaseGeneral MedicineMiddle AgedCatalaseLipoproteins LDLAdolescent; Adult; Aged; Antioxidants; Catalase; Diet High-Fat; Diet Mediterranean; Ethanol; Female; Glutathione Peroxidase; Humans; Lipoproteins LDL; Male; Middle Aged; Noncommunicable Diseases; Nutrigenomics; Oxidative Stress; Superoxide Dismutase; Young Adult; Alcoholic Beverages; Wine; Biochemistry; Aging; Cell BiologyFemaleResearch ArticleAdultmedicine.medical_specialtyAdolescentArticle SubjectLipoproteinsSOD2Diet High-FatLDLYoung Adult03 medical and health sciencesInternal medicinemedicineHumanslcsh:QH573-671Noncommunicable DiseasesAgedGlutathione PeroxidaseEthanolSuperoxide Dismutasebusiness.industryCell BiologyDietHigh-FatOxidative Stress030104 developmental biologyEndocrinologychemistryWhite WinebusinessOxidative stressOxidative Medicine and Cellular Longevity
researchProduct

Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis

2021

Objective: This study was undertaken to assess the impact of immunosuppressive and immunomodulatory therapies on the severity of coronavirus disease 2019 (COVID-19) in people with multiple sclerosis (PwMS). Methods: We retrospectively collected data of PwMS with suspected or confirmed COVID-19. All the patients had complete follow-up to death or recovery. Severe COVID-19 was defined by a 3-level variable: mild disease not requiring hospitalization versus pneumonia or hospitalization versus intensive care unit (ICU) admission or death. We evaluated baseline characteristics and MS therapies associated with severe COVID-19 by multivariate and propensity score (PS)-weighted ordinal logistic mod…

Male0301 basic medicineDimethyl FumarateNeurodegenerativemultiple sclerosis; coronavirus; pneumoniaSeverity of Illness Indexlaw.inventionImmunosuppressive AgentImmunologic Factor0302 clinical medicineNatalizumablawMonoclonalMultiple Sclerosi80 and overLungHumanizedResearch ArticlesAged 80 and overNatalizumabMiddle AgedIntensive care unitHospitalizationSettore MED/26 - NEUROLOGIAIntensive Care UnitsNeurologyMethylprednisoloneNeurologicalPneumonia & InfluenzaInterferonFemaleImmunosuppressive AgentsResearch ArticleHumanmedicine.drugAdultmedicine.medical_specialtyMusc-19 Study GroupMultiple SclerosisAdolescentClinical SciencesIntensive Care UnitClinical NeurologySettore MED/26Antibodies Monoclonal HumanizedAutoimmune DiseaseAntibodiesYoung Adult03 medical and health sciencesClinical ResearchInternal medicineSeverity of illnessmedicineHumansImmunologic FactorsMortalityAdolescent; Adult; Aged; Aged 80 and over; Antibodies Monoclonal Humanized; COVID-19; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Hospitalization; Humans; Immunologic Factors; Immunosuppressive Agents; Intensive Care Units; Interferons; Male; Middle Aged; Mortality; Multiple Sclerosis; Natalizumab; SARS-CoV-2; Severity of Illness Index; Young AdultAgedNeurology & NeurosurgeryExpanded Disability Status ScaleFingolimod HydrochlorideSARS-CoV-2business.industryMultiple sclerosisNeurosciencesCOVID-19PneumoniaOdds ratiomedicine.diseaseBrain DisordersGood Health and Well Being030104 developmental biologyOcrelizumabInterferonsNeurology (clinical)business030217 neurology & neurosurgery
researchProduct

Role of Colchicine Treatment in Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS): Real-Life Data from the AIDA Network

2020

Objective. To analyze the potential role of colchicine monotherapy in patients with tumor necrosis factor receptor associated periodic syndrome (TRAPS) in terms of control of clinical and laboratory manifestations. Methods. Patients with TRAPS treated with colchicine monotherapy were retrospectively enrolled; demographic, clinical and therapeutic data were collected and statistically analysed after having clustered patients according to different times at disease onset, penetrance of mutations, dosage of colchicine, and different disease manifestations. Results. 24 patients (14 males; 15 with pediatric disease onset) treated with colchicine monotherapy were enrolled. Colchicine resulted in …

Male0301 basic medicineEye DiseasesTRAPSColchicineAIDA NetworkGene mutationGastroenterologyReceptors Tumor Necrosis Factorchemistry.chemical_compoundSettore MED/38 - Pediatria Generale E Specialistica0302 clinical medicineReceptorsPathologyRB1-214ColchicineAge of OnsetYoung adultChildAmyloidosisAmyloidosisSyndromeMiddle AgedColchicine tumor necrosis factor TRAPSInflamacióPenetrancePhenotypeChild PreschoolFemaleJoint DiseasesResearch ArticleAdultRiskmedicine.medical_specialtyAdolescentFeverArticle SubjectImmunologyAdolescent; Adult; Age of Onset; Amyloidosis; Child; Child Preschool; Colchicine; Exanthema; Eye Diseases; Female; Fever; Humans; Joint Diseases; Male; Middle Aged; Mutation; Myalgia; Phenotype; Receptors Tumor Necrosis Factor; Retrospective Studies; Risk; Syndrome; Young AdultLower riskYoung Adult03 medical and health sciencesInternal medicinemedicineHumansPreschoolRetrospective StudiesInflammation030203 arthritis & rheumatologybusiness.industryTRAPSRetrospective cohort studyMyalgiaCell BiologyExanthemamedicine.disease030104 developmental biologychemistryMutationAge of onsetColchicineTumor Necrosis FactorbusinessMediators of Inflammation
researchProduct

Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes.

2018

BACKGROUND: Familial Mediterranean fever, mevalonate kinase deficiency (also known as the hyperimmunoglobulinemia D syndrome), and the tumor necrosis factor receptor-associated periodic syndrome (TRAPS) are monogenic autoinflammatory diseases characterized by recurrent fever flares. METHODS: We randomly assigned patients with genetically confirmed colchicine-resistant familial Mediterranean fever, mevalonate kinase deficiency, or TRAPS at the time of a flare to receive 150 mg of canakinumab subcutaneously or placebo every 4 weeks. Patients who did not have a resolution of their flare received an add-on injection of 150 mg of canakinumab. The primary outcome was complete response (resolution…

Male0301 basic medicineInterleukin-1betaFamilial Mediterranean fever0302 clinical medicineMonoclonalChildMedicine(all)Mevalonate kinase deficiencySubcutaneousMedicine (all)Interleukin-1betaAntibodies MonoclonalGeneral MedicineFamilial Mediterranean FeverRecurrent feverChild PreschoolFemaleTumor necrosis factor alphaDrugInflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5]medicine.drugAdultAdolescentFeverInjections SubcutaneousHereditary Autoinflammatory DiseasesAntibodies Monoclonal HumanizedAdolescent; Adult; Antibodies Monoclonal/administration & dosage; Antibodies Monoclonal/adverse effects; Antibodies Monoclonal/therapeutic use; Child; Child Preschool; Dose-Response Relationship Drug; Double-Blind Method; Familial Mediterranean Fever/drug therapy; Female; Fever/drug therapy; Hereditary Autoinflammatory Diseases/drug therapy; Humans; Injections Subcutaneous; Interleukin-1beta/antagonists & inhibitors; Male; Mevalonate Kinase Deficiency/drug therapy; Young AdultAntibodiesInjectionsDose-Response RelationshipYoung Adult03 medical and health sciencesAll institutes and research themes of the Radboud University Medical CenterDouble-Blind MethodGeneral & Internal MedicinemedicineHumansPreschoolAdolescent; Adult; Antibodies Monoclonal; Child; Child Preschool; Dose-Response Relationship Drug; Double-Blind Method; Familial Mediterranean Fever; Female; Fever; Hereditary Autoinflammatory Diseases; Humans; Injections Subcutaneous; Interleukin-1beta; Male; Mevalonate Kinase Deficiency; Young Adult; Medicine (all)030203 arthritis & rheumatologyDose-Response Relationship Drugbusiness.industryHereditary Autoinflammatory DiseasesHyperimmunoglobulinemia Dmedicine.diseaseCanakinumab030104 developmental biologyImmunologyMevalonate Kinase Deficiencybusiness
researchProduct

Small Bowel Carcinomas in Coeliac or Crohn’s Disease: Clinico-pathological, Molecular, and Prognostic Features. A Study From the Small Bowel Cancer I…

2017

Background and aims An increased risk of small bowel carcinoma [SBC] has been reported in coeliac disease [CD] and Crohn's disease [CrD]. We explored clinico-pathological, molecular, and prognostic features of CD-associated SBC [CD-SBC] and CrD-associated SBC [CrD-SBC] in comparison with sporadic SBC [spo-SBC]. Methods A total of 76 patients undergoing surgical resection for non-familial SBC [26 CD-SBC, 25 CrD-SBC, 25 spo-SBC] were retrospectively enrolled to investigate patients' survival and histological and molecular features including microsatellite instability [MSI] and KRAS/NRAS, BRAF, PIK3CA, TP53, HER2 gene alterations. Results CD-SBC showed a significantly better sex-, age-, and st…

Male0301 basic medicineNeuroblastoma RAS viral oncogene homologOncologySurvivalReceptor ErbB-2Colorectal cancermedicine.disease_causeInflammatory bowel diseaseInflammatory bowel diseasetumour-infiltrating lymphocyteErbB-20302 clinical medicineCrohn DiseaseRetrospective StudieRisk Factors80 and overChildClass I Phosphatidylinositol 3-KinaseAged 80 and overColonic NeoplasmSettore MED/12 - GastroenterologiaCrohn's diseaseMLH1 methylationTumour-infiltrating lymphocytesGastroenterologyGeneral MedicineMiddle AgedPrognosisInflammatory bowel disease; Microsatellite instability; MLH1 promoter methylation; Survival; Tumour-infiltrating lymphocytes; Gastroenterology030220 oncology & carcinogenesisColonic NeoplasmsSurvival AnalysiKRASHumanReceptorAdultProto-Oncogene Proteins B-rafmedicine.medical_specialtyPrognosiClass I Phosphatidylinositol 3-KinasesSettore MED/08 - Anatomia PatologicaNOProto-Oncogene Proteins p21(ras)MLH1 promoter methylationYoung Adult03 medical and health sciencesInternal medicinemedicineCarcinomaHumansMLH1 methylation; inflammatory bowel disease; microsatellite instability; survival; tumour-infiltrating lymphocytesneoplasmsAgedRetrospective StudiesInflammatory bowel disease; Microsatellite instability; MLH1 promoter methylation; Survival; Tumour-infiltrating lymphocytes; Adult; Aged; Aged 80 and over; Celiac Disease; Child; Class I Phosphatidylinositol 3-Kinases; Colonic Neoplasms; Crohn Disease; Humans; Male; Microsatellite Instability; Middle Aged; Prognosis; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Receptor ErbB-2; Retrospective Studies; Risk Factors; Survival Analysis; Tumor Suppressor Protein p53; Young Adult; Gastroenterologybusiness.industryTumour-infiltrating lymphocyteRisk FactorCancerMicrosatellite instabilityinflammatory bowel disease; microsatellite instability; MLH1 promoter methylation; tumour-infiltrating lymphocytes; survivalmedicine.diseaseSurvival Analysiseye diseasesdigestive system diseasesCeliac Disease030104 developmental biologyMicrosatellite instabilityTumor Suppressor Protein p53businessJournal of Crohn's and Colitis
researchProduct

Has VZV epidemiology changed in Italy? Results of a seroprevalence study

2017

The aim of the study was to evaluate if and how varicella prevalence has changed in Italy. In particular a seroprevalence study was performed, comparing it to similar surveys conducted in pre-immunization era. During 2013–2014, sera obtained from blood samples taken for diagnostic purposes or routine investigations were collected in collaboration with at least one laboratory/center for each region, following the approval of the Ethics Committee. Data were stratified by sex and age. All samples were processed in a national reference laboratory by an immunoassay with high sensitivity and specificity. Statutory notifications, national hospital discharge database and mortality data related to V…

Male0301 basic medicinePediatricsCross-sectional studySeroprevalenceSettore MED/42 - Igiene Generale E ApplicataAntibodies Viralmedicine.disease_causeChickenpox0302 clinical medicineChickenpox; Immunization; Seroprevalence; Surveillance; Varicella-Zoster Virus; Adolescent; Adult; Age Factors; Aged; Aged 80 and over; Antibodies Viral; Chickenpox; Child; Child Preschool; Cross-Sectional Studies; Female; Humans; Infant; Infant Newborn; Italy; Male; Middle Aged; Seroepidemiologic Studies; Young Adult; Immunology and Allergy; Immunology; PharmacologySeroepidemiologic StudiesEpidemiology80 and overImmunology and AllergyAge FactorViral030212 general & internal medicineYoung adultChildskin and connective tissue diseasesAged 80 and overSurveillanceChickenpoxVaricella-Zoster ViruAge FactorsMiddle AgedResearch PapersItalyChild PreschoolFemaleChickenpox; Immunization; Seroprevalence; Surveillance; Varicella-Zoster Virus; Immunology and Allergy; Immunology; PharmacologyHumanAdultmedicine.medical_specialtyAdolescent030106 microbiologyImmunologyAntibodiesNOYoung Adult03 medical and health sciencesChickenpox; Immunization; Seroprevalence; Surveillance; Varicella-Zoster VirusmedicineHumansSeroprevalencePreschoolAgedCross-Sectional StudiePharmacologybusiness.industrySeroepidemiologic StudieInfant NewbornVaricella zoster virusInfantSeroepidemiologic StudiesNewbornmedicine.diseaseVaricella-Zoster VirusCross-Sectional StudiesImmunizationImmunizationsense organsChickenpox Immunization Seroprevalence Surveillance Varicella-Zoster Virus Immunology and Allergy Immunology Pharmacologybusiness
researchProduct

Drug survival of anakinra and canakinumab in monogenic autoinflammatory diseases: observational study from the International AIDA Registry

2021

Abstract Objectives To investigate survival of IL-1 inhibitors in monogenic autoinflammatory disorders (mAID) through drug retention rate (DRR) and identify potential predictive factors of drug survival from a real-life perspective. Patients and methods Multicentre retrospective study analysing patients affected by the most common mAID treated with anakinra or canakinumab. Survival curves were analysed with the Kaplan-Meier method. Statistical analysis included a Cox-proportional hazard model to detect factors responsible for drug discontinuation. Results Seventy-eight patients for a total of 102 treatment regimens were enrolled. The mean treatment duration was 29.59 months. The estimated D…

Male0301 basic medicineTime FactorsSettore MED/16 - REUMATOLOGIAInterleukin-1beta0302 clinical medicineSettore MED/38 - Pediatria Generale E SpecialisticaMonoclonalPharmacology (medical)RegistriesHumanizedmedia_commonIL-1 anakinra canakinumab innovative biotechnologies monogenic autoinflammatory disorders personalized medicinepersonalized medicineMiddle AgedPenetranceTreatment OutcomeAnakinraAntirheumatic AgentsAutoinflammationIL-1; anakinra; canakinumab; innovative biotechnologies; monogenic autoinflammatory disorders; personalized medicine; Adult; Antibodies Monoclonal Humanized; Antirheumatic Agents; Female; Follow-Up Studies; Hereditary Autoinflammatory Diseases; Humans; Interleukin 1 Receptor Antagonist Protein; Interleukin-1beta; Male; Middle Aged; Retrospective Studies; Time Factors; Treatment Outcome; Young Adult; RegistriesFemalemedicine.drugAdultDrugmedicine.medical_specialtymedia_common.quotation_subjectAntibodies Monoclonal HumanizedcanakinumabAntibodiesYoung Adult03 medical and health sciencesinnovative biotechnologiesRheumatologyInternal medicinemedicineHumansAdverse effectSurvival analysismonogenic autoinflammatory disordersRetrospective Studies030203 arthritis & rheumatologyAnakinraIL-1business.industryHereditary Autoinflammatory DiseasesRetrospective cohort studyInterleukin 1 Receptor Antagonist ProteinCanakinumab030104 developmental biologyObservational studybusinessFollow-Up Studies
researchProduct